Association between serum bilirubin and cardiovascular disease in an overweight high risk population from the SCOUT trial

被引:23
作者
Jorgensen, M. E. [1 ]
Torp-Pedersen, C. [2 ]
Finer, N. [3 ]
Caterson, I. [4 ]
James, W. P. T. [5 ]
Legler, U. F. [6 ]
Andersson, C. [1 ]
机构
[1] Univ Copenhagen, Gentofte Hosp, Dept Cardiol, DK-1168 Copenhagen, Denmark
[2] Aalborg Univ, Dept Hlth Sci & Technol, Aalborg, Denmark
[3] UCL, Inst Cardiovasc Sci, Ctr Cardiovasc Prevent & Outcomes, London, England
[4] Univ Sydney, Boden Inst, Sydney, NSW 2006, Australia
[5] London Sch Hyg & Trop Med, London WC1, England
[6] Special Vocat Coll Handicapped Persons, Mainz, Germany
关键词
SCOUT; Bilirubin; Cardiovascular disease; ISCHEMIC-HEART-DISEASE; UGT1A1-ASTERISK-28; ALLELE; GILBERT-SYNDROME; SIBUTRAMINE; OUTCOMES; OBESE; LEVEL;
D O I
10.1016/j.numecd.2013.12.009
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background and aims: An inverse relationship between (serum) total bilirubin and risk of cardiovascular disease has been reported previously, but longitudinal data on overweight and obese patients are lacking. We have investigated the relationship between total bilirubin and cardiovascular adverse events in a large group of patients with risk factors for cardiovascular disease who were enrolled in a large weight loss trial. Methods and results: Data from the Sibutramine Cardiovascular Outcomes (SCOUT) trial, including almost 10.000 overweight/obese high cardiovascular risk patients, were used. The relationship between total bilirubin level at screening and the primary outcome (i.e. non-fatal myocardial infarction, non-fatal stroke, resuscitated cardiac arrest or cardiovascular death) for the entire study period was investigated using Cox proportional hazards models. The population was divided into four groups based on total bilirubin levels (normal range 5-25 mu mol/L). Time-dependent Cox analyses were also performed to adjust for weight loss over time. Initial analyses adjusted for sex, age and treatment allocation showed significantly reduced hazard ratios of 0.80 (95% confidence interval 0.68-0.94), 0.73 (0.62-0.86) and 0.77 (0.65-0.91), for the three higher total bilirubin groups: >8 and <= 10 mu mol/L, >10 and <= 13 mu mol/L and >13 mu mol/L (5-95 interpercentile range for total bilirubin at screening; 6-19 mu mol/L), compared to the lowest total bilirubin group <= 8 mu mol/L. When adjusting for classical cardiovascular risk factors, estimates increased towards unity. Additional adjustment for indicators of liver function did not alter the results. A time-dependent Cox model, adjusted for weight loss, demonstrated a similar trend. Conclusion: Bilirubin was not a risk-factor independent from other traditional cardiovascular risk-factors in our population. (C) 2014 Elsevier B. V. All rights reserved.
引用
收藏
页码:656 / 662
页数:7
相关论文
共 19 条
[11]   Oxidative Stress and Heart Failure in Altered Thyroid States [J].
Mishra, Pallavi ;
Samanta, Luna .
SCIENTIFIC WORLD JOURNAL, 2012,
[12]   Association of lower total bilirubin level with statin usage: The United States National Health and Nutrition Examination Survey 1999-2008 [J].
Ong, Kwok Leung ;
Wu, Ben J. ;
Cheung, Bernard M. Y. ;
Barter, Philip J. ;
Rye, Kerry-Anne .
ATHEROSCLEROSIS, 2011, 219 (02) :728-733
[13]   Serum total bilirubin level, prevalent stroke, and stroke outcomes: NHANES 1999-2004 [J].
Perlstein, Todd S. ;
Pande, Reena L. ;
Creager, Mark A. ;
Weuve, Jennifer ;
Beckman, Joshua A. .
AMERICAN JOURNAL OF MEDICINE, 2008, 121 (09) :781-U49
[14]   Association between the UGT1A1 TA-repeat polymorphism and bilirubin concentration in patients with intermittent claudication:: Results from the CAVASIC study [J].
Rantner, Barbara ;
Kollerits, Barbara ;
Anderwald-Stadler, Marietta ;
Klein-Weigel, Peter ;
Gruber, Ingrid ;
Gehringer, Anke ;
Haak, Markus ;
Schnapka-Koepf, Mirjam ;
Fraedrich, Gustav ;
Kronenberg, Florian .
CLINICAL CHEMISTRY, 2008, 54 (05) :851-857
[15]   Comparison of various lipid, lipoprotein, and bilirubin combinations as risk factors for predicting coronary artery disease [J].
Schwertner, HA ;
Fischer, JR .
ATHEROSCLEROSIS, 2000, 150 (02) :381-387
[16]  
SCHWERTNER HA, 1994, CLIN CHEM, V40, P18
[17]   Gilbert syndrome, UGT1A1*28 allele, and cardiovascular disease risk:: Possible protective effects and therapeutic applications of bilirubin [J].
Schwertner, Harvey A. ;
Vitek, Libor .
ATHEROSCLEROSIS, 2008, 198 (01) :1-11
[18]   Low serum bilirubin concentration is associated with coronary artery calcification (CAC) [J].
Tanaka, Muhei ;
Fukui, Michiaki ;
Tomiyasu, Ki-ichiro ;
Akabame, Satoshi ;
Nakano, Koji ;
Hasegawa, Goji ;
Oda, Yohei ;
Nakamura, Naoto .
ATHEROSCLEROSIS, 2009, 206 (01) :287-291
[19]   Gilbert syndrome and ischemic heart disease:: a protective effect of elevated bilirubin levels [J].
Vítek, L ;
Jirsa, M ;
Brodanová, M ;
Kaláb, M ;
Marecek, Z ;
Danzig, V ;
Novotny, L ;
Kotal, P .
ATHEROSCLEROSIS, 2002, 160 (02) :449-456